-
161.发明公开
公开(公告)号：KR1020130139576A
公开(公告)日：2013-12-23
申请号：KR1020120063133
申请日：2012-06-13
Applicant: 가톨릭대학교 산학협력단
IPC: A61K39/395 , A61P19/02 , A61P11/06 , A61P17/00
Abstract: The present invention relates to pharmaceutical uses of IL-2 and IL-2 antibody which are used for preventing or treating immune diseases caused by abnormality of immune responses and, more specifically, to a composition for preventing or treating immune diseases for elderly which includes IL-2 and IL-2 antibody. The IL-2 and IL-2 antibody according to the present invention can be effectively used as a pharmaceutical composition which can prevent or treat immune diseases in elderly such as autoimmune disease, inflammatory disease, and transplant rejection diseases which are caused by abnormal control of various immune responses by suppressing immune cells which are abnormally activated, suppressing activation of immune regulatory T cells (Treg) which controls inflammation responses, increasing expression of Foxp3 and STAT5, suppressing expression of Cebpb or IL-20, and having enhanced effects when IL-2 and IL-2 antibody are treated in elderly. Also the IL-2 and IL-2 antibody have no toxicity and side effects for medicine so that IL-2 and IL-2 antibody cab be used for inflammation diseases for long time, and have stable effects in vivo.
Abstract translation: 本发明涉及用于预防或治疗由免疫应答异常引起的免疫疾病的IL-2和IL-2抗体的药物用途，更具体地，涉及用于预防或治疗包括IL的老年人免疫疾病的组合物 -2和IL-2抗体。 根据本发明的IL-2和IL-2抗体可以有效地用作可以预防或治疗老年人免疫疾病的药物组合物，例如自身免疫性疾病，炎性疾病和移植排斥疾病，其由异常控制引起 通过抑制异常活化的免疫细胞，抑制控制炎症反应的免疫调节性T细胞（Treg）的激活，增加Foxp3和STAT5的表达，抑制Cebpb或IL-20的表达，并且当IL- 2和IL-2抗体在老年人中治疗。 此外，IL-2和IL-2抗体对于药物没有毒副作用，因此IL-2和IL-2抗体驾驶室长时间用于炎症疾病，并且在体内具有稳定的作用。
-
公开(公告)号：KR101273747B1
公开(公告)日：2013-06-12
申请号：KR1020100088295
申请日：2010-09-09
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/015 , A61P35/00
Abstract: 본 발명은 STA-21을 유효성분으로 포함하는 암 또는 면역질환의 예방 및 치료용 조성물에 관한 것으로서, 보다 구체적으로 본 발명은 STA-21을 화합물 또는 그의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 암 또는 면역질환의 예방 및 치료용 조성물, 면역억제용 조성물, STA-21을 이용한 미분화 T 세포의 Th17 세포로의 분화를 감소 또는 억제하는 방법 및 조절 T 세포를 활성화시키는 방법에 관한 것이다. 본 발명에 따른 STA-21 화합물은 염증성 사이토카인을 생성 및 분비하는 세포 독성 Th17 세포의 분화를 억제하는 효과가 우수하고, 비정상적으로 활성화된 면역세포의 기능을 억제하고 염증 반응을 제어하는 특성을 갖는 면역조절 T 세포(Treg)를 활성화 시키는 효과가 우수하므로 면역반응의 조절 이상으로 유발되는 자가면역질환, 염증성질환 및 이식거부질환과 같은 면역질환을 예방 및 치료할 수 있는 약학적 조성물 또는 면역 억제제로 유용하게 사용될 수 있는 효과가 있다.
-
163.发明公开자연살해세포 억제제 및 간엽줄기세포를 유효성분으로 포함하는 이식편대숙주질환의 예방 또는 치료를 위한 세포치료제 조성물 有权细胞治疗组合物，用于预防或治疗包含NK细胞抑制剂和中胚层干细胞的遗传病
公开(公告)号：KR1020130023797A
公开(公告)日：2013-03-08
申请号：KR1020110086819
申请日：2011-08-30
Applicant: 가톨릭대학교 산학협력단
IPC: A61K39/395 , A61K35/28 , A61K9/00
CPC classification number: A61K39/395 , A61K9/0019 , A61K35/28
Abstract: PURPOSE: A cell therapeutic composition containing a natural killer cell inhibitor and mesenchymal stem cells is provided to effectively suppress immune rejection responses, and to enhance a treatment effect. CONSTITUTION: A cell therapeutic composition for preventing or treating graft-versus-host diseases contains 2.5mg/kg-250mg/kg of a natural killer cell inhibitor and 2x10^5-2x10^7 mesenchymal stem cells as active ingredients. The mesenchymal stem cells are derived from human. The inhibitor is anti-asialo GM1. The composition contains is administered by intravenous or intradural injection.
Abstract translation: 目的：提供含有天然杀伤细胞抑制剂和间充质干细胞的细胞治疗组合物，以有效抑制免疫排斥反应，提高治疗效果。 构成：用于预防或治疗移植物抗宿主病的细胞治疗组合物含有2.5mg / kg-250mg / kg的天然杀伤细胞抑制剂和2x10 ^ 5-2x10 ^ 7间充质干细胞作为活性成分。 间充质干细胞来源于人。 抑制剂为抗脱唾液酸GM1。 组合物含有通过静脉内或硬膜外注射施用。
-
公开(公告)号：KR1020120118596A
公开(公告)日：2012-10-29
申请号：KR1020110036053
申请日：2011-04-19
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/497 , A61K31/495 , A61K31/4164 , A61P37/00
CPC classification number: A61K31/496 , Y10S514/825
Abstract: PURPOSE: A composition for preventing and treating immunization diseases including nutlin-3a compound is provided to suppress the expression of IL-17 through overexpression of p53. CONSTITUTION: A composition for preventing and treating immunization diseases includes nutlin-3a compound. The nutlin-3a compound suppresses the IL-17 production. The IL-17 production suppression is completed by the overexpression of p53. The immunization disease is autoimmune disease, inflammation disease, transplantation rejection disease of cell, tissue or organ. The autoimmune disease or inflammation disease is rheumatoid arthritis, asthma], dermatitis, psoriasis, cystic fibrosis, multiple sclerosis, systemic lupus erythematosus, sjogren syndrome, hashimoto thyroiditis, polymyositis, scleroderma, Addison disease, vitiligo, pernicious anemia, glomerulonephritis, pulmonary fibrosis, inflammatory Bowel dieseses, autoimmune diabetes, diabetic retinopathy, rhinitis, ischemia-reperfusion injury, post-angioplasty restenosis, chronic obstructive pulmonary diseases(COPD), Graves disease, gastrointestinal allergies, conjunctivitis, and atherosclerosis. [Reference numerals] (AA) Producing amount of IL-17(pg/ml)
Abstract translation: 目的：提供一种预防和治疗包括nutlin-3a化合物在内的免疫疾病的组合物，以通过p53的过表达抑制IL-17的表达。 构成：用于预防和治疗免疫疾病的组合物包括nutlin-3a化合物。 Nutlin-3a化合物抑制IL-17的产生。 IL-17产生抑制由p53的过表达完成。 免疫疾病是自身免疫性疾病，炎症疾病，细胞，组织或器官的移植排斥疾病。 自身免疫疾病或炎症疾病是类风湿性关节炎，哮喘，皮炎，牛皮癣，囊性纤维化，多发性硬化，系统性红斑狼疮，干燥综合症，麻疹甲状腺炎，多发性肌炎，硬皮病，艾迪生病，白癜风，恶性贫血，肾小球性肾炎，肺纤维化， 炎性肠病，自身免疫性糖尿病，糖尿病性视网膜病变，鼻炎，缺血再灌注损伤，血管成形术后再狭窄，慢性阻塞性肺疾病（COPD），格雷夫斯病，胃肠道过敏，结膜炎和动脉粥样硬化。 （标号）（AA）IL-17的产生量（pg / ml）
-
公开(公告)号：KR1020120061025A
公开(公告)日：2012-06-12
申请号：KR1020110049894
申请日：2011-05-26
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/166 , A61K31/16 , A61K31/06 , A61P21/00
Abstract: PURPOSE: A composition containing AG490 compounds is provided to enhance regulatory T cell(Treg) activity and to prevent or treat immune diseases. CONSTITUTION: A composition for preventing or treating immune diseases contains AG490 compounds of chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient. The immune diseases are autoimmune diseases, inflammatory diseases, and transplantation rejection. A method for reducing or suppressing differentiation of undifferentiated T cells in vitro into Th17 cells comprises a step of treating AG490 compounds or pharmaceutically acceptable salt thereof to the undifferentiated T cells.
Abstract translation: 目的：提供含有AG490化合物的组合物以增强调节性T细胞（Treg）活性并预防或治疗免疫疾病。 构成：用于预防或治疗免疫疾病的组合物含有化学式1的AG490化合物或其药学上可接受的盐作为活性成分。 免疫疾病是自身免疫性疾病，炎性疾病和移植排斥反应。 将体外未分化T细胞分化为Th17细胞的方法包括将AG490化合物或其药学上可接受的盐治疗至未分化T细胞的步骤。
-
Patent Agency Ranking
公开(公告)号：KR1020110100700A
公开(公告)日：2011-09-15
申请号：KR1020100019671
申请日：2010-03-05
Applicant: 가톨릭대학교 산학협력단 , 한림제약(주)
IPC: A61K31/4704 , A61K9/14 , A61K47/38 , A61P19/02
CPC classification number: A61K31/4704 , A61K9/2004
Abstract: 본 발명은 레바미피드 및 약학적으로 허용가능한 담체를 포함하는 골관절염의 예방 또는 치료용 약학 조성물을 제공한다. 상기 약학 조성물은 경구 투여용 형태일 수 있으며, 바람직하게는 정제 또는 캅셀제 형태의 고형 경구용 제형을 가질 수 있다. 또한, 상기 약학 조성물은 레바미피드가 0.5 내지 50 mg/kg, 더욱 바람직하게는 0.6 내지 6 mg/kg의 용량으로 경구투여되기에 적합한 단위 투여 형태(unit dosage form)로 제제화될 수 있다.
-
公开(公告)号：KR101004363B1
公开(公告)日：2010-12-28
申请号：KR1020100024700
申请日：2010-03-19
Applicant: 한국생명공학연구원 , 가톨릭대학교 산학협력단
Inventor： 박영우 , 조기원 , 유석호 , 유정 , 윤선하 , 박지현 , 송은정 , 이종호 , 서민지 , 조선정 , 조미라 , 김호연 , 박미경 , 오혜좌 , 박진실 , 우윤주
CPC classification number: C07K14/7151 , C07K14/7155 , C07K2319/00
Abstract: PURPOSE: A TNFR2-IL21R fusion protein as a double antagonist to TNF-alpha and IL-21 is provided to reduce inflammatory cytokine secretion and to increase anti-inflammatory cytokine secretion. CONSTITUTION: A composition for preventing and treating autoimmune disease contains a fusion protein having a fragment with extracellular region of TNFR2(Tumor necrosis factor receptor type 2) or TNFR2 and a fragment with extracellular region of IL21R(Interleukin-21 receptor) protein or IL21R as an active ingredient. The fusion protein has an amino acid sequence of sequence number 1.
Abstract translation: 目的：提供TNFR2-IL21R融合蛋白作为TNF-α和IL-21的双重拮抗剂，以减少炎症细胞因子分泌和增加抗炎细胞因子分泌。 构成：用于预防和治疗自身免疫疾病的组合物含有具有TNFR2细胞外区域（2型肿瘤坏死因子受体）或TNFR2的片段和IL21R（白细胞介素-21受体）蛋白或IL21R的细胞外区域的片段的融合蛋白，作为 活性成分。 融合蛋白具有序列号1的氨基酸序列。
-
168.发明公开
公开(公告)号：KR1020100067708A
公开(公告)日：2010-06-22
申请号：KR1020080126216
申请日：2008-12-12
Applicant: 가톨릭대학교 산학협력단 , 에이치 엘 지노믹스(주)
CPC classification number: A61K36/87
Abstract: PURPOSE: A pharmaceutical composition containing Vitis vinifera seed extract is provided to suppress osteoclast differentiation and to prevent and treat osteoporosis. CONSTITUTION: A pharmaceutical composition for preventing or treating osteoporosis contains Vitis vinifera seed extract and pharmaceutically acceptable carrier. The Vitis vinifera seed extract has 80-130 of procyanidolic value(PCV), 30% or less (+) catechin and (-) epicatechin, and 95-105% of proanthocyanine. A method for manufacturing the Vitis vinifera seed extract comprises: a step of adding mixture solvent of water and acetone to pulverized Vitis vinifera seed and extracting at room temperature; a step of removing acetone and suturing sodium chloride and filtering; a step of extracting the extract with acetate and concentrating; and a step of adding chloroform to the concentrate and filtering.
Abstract translation: 目的：提供含有葡萄籽提取物的药物组合物，以抑制破骨细胞分化和预防和治疗骨质疏松症。 构成：用于预防或治疗骨质疏松症的药物组合物含有葡萄种子提取物和药学上可接受的载体。 葡萄籽提取物的原花青素值（PCV）为80-130，儿茶素和（ - ）表儿茶素为30％以下，原花青素为95-105％。 葡萄种子提取物的制造方法包括：将水和丙酮的混合溶剂加入粉状葡萄种子并在室温下提取的步骤; 去除丙酮并缝合氯化钠并过滤的步骤; 用醋酸提取提取物浓缩的步骤; 以及向浓缩物中加入氯仿并过滤的步骤。
-
公开(公告)号：KR100601080B1
公开(公告)日：2006-07-19
申请号：KR1020040067389
申请日：2004-08-26
Applicant: 가톨릭대학교 산학협력단 , 주식회사 다림바이오텍
IPC: A61K31/353 , A61K31/352
Abstract: 본 발명은 녹차의 폴리페놀 중 하나인 (-)-에피갈로카테킨 갈레이트(EGCG)를 유효성분으로 함유하는 류마티스 관절염 치료제에 관한 것이다. EGCG를 류마티스 관절염 동물모델에 1㎎ 내지 100㎎/㎏의 용량으로 투여하면, 용량 의존적으로 유의성을 지니는 류마티스 관절염 치료효과가 발명되었다.
에피갈로카테킨 갈레이트, 녹차, 류마티스 관절염, 자가면역질환, 사이토카인, T 세포, 치료제-
170.发明公开
公开(公告)号：KR1020040079393A
公开(公告)日：2004-09-14
申请号：KR1020040067389
申请日：2004-08-26
Applicant: 가톨릭대학교 산학협력단 , 주식회사 다림바이오텍
IPC: A61K31/353 , A61K31/352
Abstract: PURPOSE: A composition containing epigallocatechin gallate (EGCG) as one of green tea polyphenols as an effective ingredient is provided. The EGCG controls an inflammatory reaction in the lesion area of rheumatoid arthritis and a cell-mediated immune reaction which specifically reacts with an antigen and thus has a therapeutic effect on rheumatoid arthritis. CONSTITUTION: The agent for the treatment of rheumatoid arthritis contains (-)-epigallocatechin gallate and a pharmaceutically acceptable carrier such as physiological saline. The dosage of EGCG is 1 to 100mg/kg. The EGCG is administered in the form of an EGCG-PLGA complex by impregnating into a PLGA(poly/lactide/glycolide) polymer.
Abstract translation: 目的：提供含有表没食子儿茶素没食子酸酯（EGCG）作为绿茶多酚作为有效成分的组合物。 EGCG控制类风湿性关节炎的病变区域的炎症反应和与抗原特异性反应的细胞介导的免疫反应，因此对类风湿性关节炎具有治疗作用。 构成：用于治疗类风湿关节炎的药物含有（ - ） - 表没食子儿茶素没食子酸酯和药学上可接受的载体如生理盐水。 EGCG剂量为1〜100mg / kg。 通过浸渍到PLGA（聚丙交酯/乙交酯）聚合物中，EGCG以EGCG-PLGA复合物的形式施用。
-
-
-
-
-
-
-
-
-
Search Results
262
records
(took 0.034 seconds)
